Ipamorelin: selective GH secretagogue
Ipamorelin is a synthetic pentapeptide (711.9 Da), a selective ghrelin receptor (GHS-R) agonist. In preclinical models, it stimulates GH release without significant effects on cortisol, prolactin, or aldosterone. The effect depends on the dose, which allows precise titration in research protocols.
CJC-1295: GHRH analog
CJC-1295 with DAC is a modified peptide with a half-life of 6 to 8 days, producing longer-lasting GH and IGF-1 elevation. Mod GRF 1-29 (without DAC) has a shorter half-life of about 30 minutes and a more pulsatile GH release, closer to the natural pattern. Both available at Peptid.si.
Combination in research
CJC-1295 acts on the GHRH receptor (GH synthesis); Ipamorelin acts on the ghrelin receptor (pulsatile release). Preclinical models suggest that combining both pathways produces greater GH release than either peptide alone.
Limitations of evidence
Most data is preclinical. Human data exists for CJC-1295 with DAC from early clinical phases, but the studies never progressed to approval. Neither peptide is approved for medical use, and both remain research compounds.
References / Links
- Raun K, Hansen BS, Johansen NL, Thøgersen H, et al. (1998). Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. PubMed
- Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA (2006). Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. Oxford Academic
- Ionescu M, Frohman LA (2006). Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. J Clin Endocrinol Metab. Oxford Academic
- Alba M, Fintini D, Sagazio A, Lawrence B, et al. (2006). Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. Am J Physiol Endocrinol Metab. PubMed
- Johansen PB, Nowak J, Skjaerbaek C, Frost L, et al. (1999). Ipamorelin, a new growth-hormone-releasing peptide, induces longitudinal bone growth in rats. Growth Horm IGF Res. ScienceDirect
